I am strongly considering investing in your company. Just a few questions. What is your realistic plan of exit and projected timeline in order for investors to see a ROI? Also, are there any plans for future fundraising that would dilute the investment? If so, how many? Thank ...

Hi Bugg! Thanks for your interest and for your questions. I responded to your direct message. Let me know if you have further questions. We would be grateful to have you join our mission! Best, Liz

Thank you for the detailed response. I now feel comfortable with investing. Just one final clarification, however, on the planned $20M Series A: Do you have an estimated pre-money valuation or valuation range at which you expect to raise the Series A? I'm trying to understand ...

While we cannot guarantee a specific valuation for our upcoming Series A round, we currently anticipate the pre-money valuation of Sempresto to be somewhere in the range of $75M to $100M.To answer your question regarding a potential acquisition: yes, if Sempresto were to be acquired prior to launch, Wefunder shareholders would benefit. At this time, Sempresto has only common and Seed Series preferred shares, which convert to common stock on a 1:1 basis. In the event of an acquisition, all sha...

Hi Elizabeth, Pirouette Pharma is also developing a next-generation epinephrine auto-injector, but with a different approach focused on ease of use and a hidden-needle OnePush platform, while Sempresto is focused more on portability by integrating the injector with a smartphon...

Hi Glenn. This is a great question! We believe that patients deserve more options and that each person's needs are unique. Certainly, fear of needles is a consideration for some patients, but recent data shows that less than 20% of patients cite this as a major concern. However, over 60% of patients report not having their epinephrine with them when anaphylaxis occurs, so failure to carry is arguably the most important barrier to prompt administration of epinephrine. That is the issue we are ...

Hello Elizabeth, I run a crowdfunding club investing in Planet Positive deals. Congratulations on Sempresto, I think it looks promising and I know our members will also think so. Would you like to discuss announcing your offering to our club? Feel free to select a convenient t...

Hi Mark, I would be happy to connect and learn more about Planet Positive. I've chosen a time on your calendar. I look forward to meeting you! Best, Liz

I think this is a brilliant idea. My concern is that by your own timeline, market acceptance is 5 years away and phone design is evolving rapidly. How much of your design, patent IPO and FDA approval depends on the shape of the phone itself? We already have foldable phones bre...

Hi Jason, This is a great question. Our research indicates that more than 97% of the current US smartphone user base uses a conventional style smartphone. Although foldables are increasing, they are still only 1-3% of the market and only projected to reach ~3-5% by the end of the decade, even with Apple entering the market. We will, of course, continue monitoring this trend and may adjust the design to accommodate the new form factor, if necessary. Importantly, our core IP centers around atta...

Sempresto Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

Backed by $2.6M angel investment and Jefferson University Partnership

FDA filing targeted within 18 months via the 505(b)(2) pathway

Medtech leadership team trained at Harvard, MIT, Wharton, Johns Hopkins & UPenn Medicine

Red Dot award-winning autoinjector that attaches to a smartphone, compatible with 95% of phones

15 patents granted, 10 pending across phone-based autoinjector technology (US & ex-US)

Targeting a $3B+ addressable market; 33M Americans living with food allergies

World-class team with 3 IPOs and 30+ commercial product launches

85%+ projected gross margins at scale, priced below the current market average (not guaranteed)

Sempresto

Quick facts

Team profiles

Featured investor profiles

Updates